Alopexx, Inc.

Alopexx is a clinical-stage biotechnology company developing immune therapeutics to prevent and treat microbial infections without antibiotics, targeting a protein called PNAG found on the surface of multiple bacterial and fungal pathogens. The company aims to address antimicrobial resistance by using active vaccination and passive immunotherapies as alternatives to antibiotic treatments.